Irantechs Innovationszentrum

Unser Angebot

 Partnerschaftsmöglichkeiten entdecken 
​​​​​​​Service und Partnerschaft mit der iranischen Biotechnologie- und Life-Sciences-Community

​​​​​​​​​​​​​​Von Förder- und Finanzierungsnetzwerken über internationale Delegationen und Messebeteiligungen bis hin zu Ihren Veranstaltungen bieten wir Ihnen umfassende Unterstützung und Plattformen für die Biotechnologie- und Life-Sciences-Community im Nahen Osten und im Iran. Profitieren Sie von unserer Expertise, unseren Netzwerken und unseren maßgeschneiderten Dienstleistungen, um Ihr Netzwerk im Nahen Osten erfolgreich auszubauen.

Deutsche Innovationszentren und Start-ups im Biotechnologiesektor können ihre Reichweite durch Partnerschaften mit Irantech erweitern. Diese Kooperation ermöglicht den Zugang zu skalierbarer Produktion, kosteneffizienter Entwicklung und aufstrebenden Gesundheitsmärkten im Iran und der MENA-Region. Sie schafft Synergien für eine duale Marktstrategie und beschleunigt grenzüberschreitende Innovationen.

Our accelerator program

Positionierung in Schwellenmärkten durch strategische Partnerschaften im Nahen Osten

III

DELEGATION

Wir organisieren maßgeschneiderte Delegationsreisen

II

KOFINANZIERUNG

Geschäftschancen nutzen, Partnerschaftsprojekte starten

I

NETZWERK

Vernetzung für Fortschritt und Innovation

UNSERE DIENSTLEISTUNGEN

Für Startups und mittelständische Unternehmen, die sich in einem dynamischen Markt erfolgreich positionieren wollen, ist dieses Netzwerk besonders wichtig. Wir fördern aktiv die Vernetzung zwischen Unternehmen, Forschungseinrichtungen und Investoren aus dem Nahen Osten auf nationaler und internationaler Ebene. Darüber hinaus bringen wir erfahrene Fachleute, Pre-Seed-Kapital und Co-Investment-Modelle in gemeinsame Projekte ein – sowohl in Deutschland als auch direkt vor Ort in Iran. Unser Ziel ist es, Innovationen zu beschleunigen, Synergien zu schaffen und nachhaltige Partnerschaften zwischen den Märkten zu etablieren.

Netzwerke heute

Das Irantech Innovationszentrum bietet strategischen Zugang zu Expertennetzwerken, Startkapital und Co-Investitionsmöglichkeiten – entweder in Deutschland oder direkt im Iran. Wir verbinden iranische Startups und Biotech-Zentren mit Sitz in Deutschland mit skalierbaren Produktionspartnern, Zugang zu Schwellenmärkten und gemeinsamen Entwicklungspfaden.
Ob iranische KMU auf der Suche nach Frühphasenfinanzierung, Technologietransfer oder regionaler Expansion sind – unsere Plattform ist darauf ausgerichtet, Innovationen zu beschleunigen und nachhaltige grenzüberschreitende Partnerschaften aufzubauen.

Kofinanzierung

Delegation

Wir planen und organisieren auch maßgeschneiderte Delegationsreisen in die EU. Darüber hinaus begrüßen wir ausländische Delegationen und pflegen deren Vernetzung. Wir bieten engagierte Networking- und Investitionsmöglichkeiten für neue, aufstrebende iranische Startups mit Sitz in der EU. Unsere Mission ist es, vielversprechende Pharma- und Biotech-Kompetenzen zwischen dem Iran und Europa zu bündeln. Wir betrachten NRW als eine Region mit einzigartiger Positionierung. Diese Stärken passen perfekt zu unserem Ziel, die pharmazeutische Wertschöpfungskette von einfachen Generika über komplexe Biosimilars und Spezialmedikamente bis hin zu digital verbesserten Therapeutika zu modernisieren.

PLAN

In dieser Phase werden Ziele festgelegt und ein Plan zu deren Erreichung erstellt. Dazu gehören:
Identifizierung der Chancen, Analyse der aktuellen Situation, Festlegung der Ziele und der Methoden zur Zielerreichung.

UMSETZEN

Das im vorherigen Schritt entwickelte Programm wird in diesem Schritt umgesetzt. Wichtig ist:
Eine Pilot- oder begrenzte Implementierung wird empfohlen. Eine sorgfältige Aufzeichnung von Daten und Beobachtungen ist unerlässlich.

AKTIVITÄT ÜBERPRÜFEN

In dieser Phase werden die wirtschaftlichen Ergebnisse der Programmimplementierung mit den ursprünglichen Zielen verglichen: Wir analysieren Daten und Leistung. Wir identifizieren Schwächen und Stärken.
Auf Grundlage der Überprüfungen werden Korrekturmaßnahmen ergriffen:
Erfolge konsolidieren, Programm im nächsten Zyklus überarbeiten.

Vielversprechende Bereiche für die Zusammenarbeit zwischen Iran und Deutschland

  • Advanced Manufacturing & Industry 4.0Automation, continuous manufacturing, process analyticsAI-driven optimization for pharmaceutical production
  • Green Chemistry & SustainabilityExpertise in reducing environmental footprintSolvent reduction, energy efficiency, waste minimization
  • Regulatory Science & QualityProximity to strong regulatory bodies (national/EU-level thinking)
  • Excellence in GMP standards and compliance 
    ​​​​​​​Specialized Research    Strong capabilities in oncology, infectious diseases, neurology, cardiovascular and metabolic disorders
  • Digital HealthIntegration of diagnostics, monitoring, and treatment technologies
  • Logistics HubCentral location in EuropeMajor transport infrastructure (ports, rail, road)

2. Specialty and Orphan Drugs

Why: This collaboration moves beyond simple generics—where Iran has scale—and targets high-value segments where NRW excels in advanced R&D and pharmaceutical manufacturing. Biosimilars represent a globally strategic growth area.

Iran’s Role: Expertise in complex API production and cost-effective biosimilar manufacturing, supported by scalable infrastructure and potential for technology transfer.

NRW’s Role: Advanced formulation technologies (e.g., controlled release, solubility enhancement), biologics manufacturing expertise, rigorous QA/QC systems, and regulatory strategy (especially EMA), plus access to EU-based CMOs/CDMOs for final or specialized stages.

NRW Partners:
  • BioClusters in Cologne, Düsseldorf, and Aachen–Jülich (oncology and cardiovascular focus)
  • Forschungszentrum Jülich (bioprocessing and modeling)
  • University Hospitals (clinical trial networks)
  • Specialized CDMOs with advanced capabilities

1. High-Quality Complex Generics and Biosimilars

  • Combining Iran’s generic drug manufacturing capabilities with NRW’s leadership in digital health creates high-value therapeutic products for EU and global markets.
  • Iran’s Role: Manufacturing therapeutic components such as connected inhalers, smart injectors, pill bottles with digital tracking, and companion drugs for digital therapies.
  • NRW’s Role: Developing digital platforms (apps, sensors, AI analytics), navigating regulatory pathways for Software as a Medical Device (SaMD) and combination products, user experience design, and clinical validation.

3. Digital Health Integration for Therapeutics

Why: The EU is increasing pressure for greener pharmaceutical practices. Iran offers scalable API manufacturing capacity, while NRW contributes advanced green chemistry and process intensification technologies.

Iran’s Role:
  • Large-scale API production capacity
  • Potential for joint process optimization with NRW technologies
    Development and transfer of green chemistry technologies (e.g., catalysis, biocatalysis, flow chemistry, solvent reduction/replacement)

NRW’s Role:
  • Process Analytical Technology (PAT) for optimization
  • Expertise in Life Cycle Assessment (LCA)

    4. Sustainable and Cost-Effective API Production

    Pharmaceutical Biotechnology Joint development of advanced therapies, including biopharmaceuticals and gene-based treatments. NRW’s innovation hubs support personalized medicine, while Iran offers scalable production and cost-efficient capabilities.
    Complex Generics & Biosimilars Iran’s strength in API manufacturing and formulation meets NRW’s expertise in regulatory strategy, QA/QC systems, and advanced drug delivery technologies.
    Digital Therapeutics & Smart Health Integration of Iranian digital platforms with German precision in diagnostics, monitoring, and therapy design.
    Sustainable API Production Collaboration in green chemistry and energy-efficient manufacturing, leveraging Iran’s industrial base and NRW’s sustainability-driven R&D.
    Clinical Research & Regulatory Alignment Access to EU clinical trial networks and regulatory pathways via NRW, with Iran contributing patient populations and trial infrastructure.
    Strategic Market Access Iran’s proximity to Middle Eastern and Central Asian markets complements NRW’s gateway to the EU, enabling dual-market strategies.

    Pharmaceutical biotechnology

    • Sustainable Production Technologies Iran’s industrial base and enzyme engineering capabilities complement NRW’s leadership in bio-based manufacturing and process innovation.

    • Biofuels & Waste Valorization Joint development of biofuels and biogas from organic waste, leveraging Iran’s feedstock availability and NRW’s advanced biorefinery models.

    • Green Cleaning & Biosurfactants Collaboration on eco-friendly cleaning agents using microbial biosurfactants, with NRW’s R&D networks and Iran’s scalable production.

    • Climate-Friendly Industrial Solutions NRW’s targeted funding and Irantech’s pilot-scale infrastructure enable rapid deployment of low-emission technologies across sectors.

    Industrial biotechnology

    • Bioplastics & Sustainable Materials Iran’s polymer expertise and feedstock availability complement NRW’s R&D in bioplastics and biodegradable alternatives to petroleum-based products.

    ​​​​​​​

    • Agro-Biotech & Natural Inputs Joint development of biofertilizers and biopesticides using microbial and plant-based solutions, reducing chemical dependency in agriculture.


    • Circular Bioeconomy Models Iran’s industrial scale and NRW’s innovation networks enable closed-loop systems for biomass utilization and waste-to-resource conversion.

    ​​​​​​​

    • Strategic Ecosystem Building NRW’s funding programs and Irantech’s regional clusters foster science–industry partnerships for scalable, climate-friendly solutions.

    Bioeconomy 
    ​​​​​​​& Resources

    Strategic Collaboration Potential

    • The greatest opportunity to upgrade the pharmaceutical value chain—from simple generics to complex generics, biosimilars, specialty/orphan drugs, and digitally enhanced therapeutics—lies in combining Iran’s production scale and cost efficiency with North Rhine-Westphalia’s advanced technologies, robust quality systems, and regulatory expertise.

    • Sustainable API manufacturing is another high-potential area for bilateral cooperation, especially in the context of global supply chain diversification and green chemistry.

    • North Rhine-Westphalia (NRW), with its dense ecosystem of biotech clusters, academic institutions, and industrial partners, is the ideal German region for Iranian pharmaceutical manufacturers seeking to:

    • Enhance their technological capabilities

    • Align with EU regulatory standards

    • Access the European market through strategic partnerships

    Irantech Innovationszentrum actively facilitates these connections, offering matchmaking, delegation support, and joint development opportunities.​​​​​​​

    • Advanced Manufacturing & Industry 4.0: Expertise in automation, continuous manufacturing, process analytics, and AI-driven optimization.
    • Green Chemistry & Sustainability: Specialized in minimizing environmental footprint through solvent reduction, energy efficiency, and waste minimization.
    • Scientific Excellence & Regulatory Quality: Proximity to strong regulatory bodies (national/EU-level thinking) and leadership in GMP standards.
    • Specialized Research: Strong capabilities in oncology, infectious diseases, neurology, cardiovascular, and metabolic disorders.
    • Digital Health Integration: Seamless fusion of diagnostics, monitoring, and therapeutic solutions.

    • Central Logistics Hub: Strategically located in Europe with access to major transport infrastructure (ports, railways, highways).

    Key Strengths of Our Innovation Centers in Europe Relevant to Iran

    • Established Generic Manufacturing: Large-scale production of small-molecule generics and essential medicines.
    • API Production Capability: Significant capacity for manufacturing Active Pharmaceutical Ingredients (APIs), including certain complex molecules.
    • Cost Competitiveness: Lower production costs compared to Western Europe.​​​​​​​
    • Regional Market Access: Strong positioning in Middle Eastern, Central Asian, and CIS markets.

    Key Strengths of the Iranian Market for Strategic Collaboration

    • Established Pharmaceutical Manufacturing Base: Iran has a strong foundation in generic drug production, including large-scale manufacturing of essential small-molecule medicines and complex APIs.

    • Cost-Efficient Production Capacity: Competitive labor and operational costs offer significant advantages for scaling pharmaceutical development compared to Western Europe.

    • Strategic Access to Regional Markets: Positioned at the crossroads of the Middle East, Central Asia, and CIS countries, Iran provides direct access to fast-growing healthcare markets.

    • Emerging Innovation Ecosystem: A growing network of biotech startups, academic institutions, and industrial partners is driving innovation in oncology, infectious diseases, and digital therapeutics.
      ​​​​​​​

    • Complementary Capabilities for EU Collaboration: Iran’s industrial scale and production expertise align with Germany’s advanced technologies, regulatory systems, and R&D leadership—creating a powerful synergy for joint development and market expansion.

    Why Iran and the Middle East
    ​​​​​​​Are Especially Suited for This Collaboration

    • BIO.NRW as a Strategic Umbrella BIO.NRW is the official umbrella brand for all regional life sciences networks in North Rhine-Westphalia, commissioned by the Ministry of Economic Affairs, Industry, Climate Action and Energy (MWIKE). It actively promotes NRW as a biotech hub across Germany and internationally.

      Integrated Life Sciences Ecosystem Includes key regional clusters such as BioCologne, BioIndustry e.V., BioRiver e.V., LifeScienceNet Düsseldorf, MedLife e.V., and Gesellschaft für Bioanalytik Münster e.V. These networks offer targeted matchmaking, innovation support, and access to specialized expertise.

      Comprehensive Support Services From accelerator programs and funding guidance to international delegation trips and trade fair participation (e.g., BIO-Europe, BIO International Convention), NRW provides a full suite of services to support biotech growth.

      Robust Investor Network NRW hosts one of Germany’s largest biotech investor ecosystems, including bi-monthly investor circles and the annual Business Angel Congress (BAC), connecting startups with capital and strategic partners.

      Global Market Access & Visibility Through joint stands at major industry events and a strong presence in EU-level initiatives, NRW offers unparalleled access to European and global markets.

      Advanced Research & Regulatory Expertise Home to world-class institutions like Max Planck Institutes, Forschungszentrum Jülich, Fraunhofer Institutes, and leading universities (RWTH Aachen, University of Bonn, University of Cologne, HHU Düsseldorf), NRW excels in cutting-edge R&D and regulatory strategy.

    Why German Partners
    ​​​​​​​Are Especially Suited for This Collaboration

    Irantech Innovationszentrum serves as a gateway for strategic collaboration between German life sciences networks and emerging pharmaceutical ecosystems in the Middle East. We work closely with regional clusters, research institutions, and production partners to build scalable, cost-effective, and innovation-driven partnerships.
    Our network includes:
    Leading production hubs across Iran and the Middle East

    • Academic and clinical research partners in oncology, infectious diseases, and digital therapeutics
    • Specialized API manufacturers with capabilities in complex molecules
    • Technology transfer facilitators for biosimilars, green chemistry, and digital health integration​​​​​​​

      Do you need advice?